Related references
Note: Only part of the references are listed.Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis
Wen Wen et al.
ANNALS OF MEDICINE (2022)
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety
Peter Breining et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Markus Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Camostat mesilate therapy for COVID-19
Yoshiharu Uno
INTERNAL AND EMERGENCY MEDICINE (2020)
COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives
Jiumeng Sun et al.
TRENDS IN MOLECULAR MEDICINE (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience
Markos Kalligeros et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
Sheng-Wen Huang et al.
BIOMEDICAL JOURNAL (2020)
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
Spinello Antinori et al.
PHARMACOLOGICAL RESEARCH (2020)
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
Mizuki Yamamoto et al.
VIRUSES-BASEL (2020)
Preventing the Interaction between Coronaviruses Spike Protein and Angiotensin I Converting Enzyme 2: AnIn SilicoMechanistic Case Study on Emodin as a Potential Model Compound
Luca Dellafiora et al.
APPLIED SCIENCES-BASEL (2020)
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Jianhui Nie et al.
EMERGING MICROBES & INFECTIONS (2020)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
Mizuki Yamamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Protease inhibitors targeting coronavirus and filovirus entry
Yanchen Zhou et al.
ANTIVIRAL RESEARCH (2015)
Tongkat Ali (Eurycoma longifolia Jack): A review on its ethnobotany and pharmacological importance
Rajeev Bhat et al.
FITOTERAPIA (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
Tin-Yun Ho et al.
ANTIVIRAL RESEARCH (2007)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Share Paper
